For example, the predominate type I enzyme PRMT1 methylates epidermal growth factor receptor (EGFR) to promote colorectal tumor growth in a xenograft model, and high EGFR methylation is associated with resistance to cetuximab treatment and reduced overall survival in patients with colorectal cancer (21). Here, EGFR is linked to colorectal cancer.